1
|
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz
P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S and Stern
T: Effects of atorvastatin on early recurrent ischemic events in
acute coronary syndromes: the MIRACL study: a randomized controlled
trial. JAMA. 285:1711–1718. 2001. View Article : Google Scholar
|
2
|
Briguori C, Colombo A, Airoldi F, et al:
Statin administration before percutaneous coronary intervention:
impact on periprocedural myocardial infarction. Eur Heart J.
25:1822–1828. 2004. View Article : Google Scholar
|
3
|
Cannon CP, Braunwald E, McCabe CH, Rader
DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA and Skene
AM: Intensive versus moderate lipid lowering with statins after
acute coronary syndromes. N Engl J Med. 350:1495–1504. 2004.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Chang SM, Yazbek N and Lakkis NM: Use of
statins prior to percutaneous coronary intervention reduces
myonecrosis and improves clinical outcome. Catheter Cardiovasc
Interv. 62:193–197. 2004. View Article : Google Scholar : PubMed/NCBI
|
5
|
de Lemos JA, Blazing MA, Wiviott SD, et
al: Early intensive vs a delayed conservative simvastatin strategy
in patients with acute coronary syndromes: phase Z of the A to Z
trial. JAMA. 292:1307–1316. 2004.
|
6
|
Pasceri V, Patti G, Nusca A, Pristipino C,
Richichi G and Di SG; ARMYDA Investigators. Randomized trial of
atorvastatin for reduction of myocardial damage during coronary
intervention: results from the ARMYDA (Atorvastatin for Reduction
of MYocardial Damage during Angioplasty) study. Circulation.
110:674–678. 2004. View Article : Google Scholar
|
7
|
Mood GR, Bavry AA, Roukoz H and Bhatt DL:
Meta-analysis of the role of statin therapy in reducing myocardial
infarction following elective percutaneous coronary intervention.
Am J Cardiol. 100:919–923. 2007. View Article : Google Scholar : PubMed/NCBI
|
8
|
Patti G, Pasceri V, Colonna G, Miglionico
M, Fischetti D, Sardella G, Montinaro A and Di SG: Atorvastatin
pretreatment improves outcomes in patients with acute coronary
syndromes undergoing early percutaneous coronary intervention:
results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol.
49:1272–1278. 2007. View Article : Google Scholar
|
9
|
Briguori C, Visconti G, Focaccio A, Golia
B, Chieffo A, Castelli A, Mussardo M, Montorfano M, Ricciardelli B
and Colombo A: Novel approaches for preventing or limiting events
(Naples) II trial: impact of a single high loading dose of
atorvastatin on periprocedural myocardial infarction. J Am Coll
Cardiol. 54:2157–2163. 2009. View Article : Google Scholar
|
10
|
Di Sciascio G, Patti G, Pasceri V,
Gaspardone A, Colonna G and Montinaro A: Efficacy of atorvastatin
reload in patients on chronic statin therapy undergoing
percutaneous coronary intervention: results of the ARMYDA-RECAPTURE
(Atorvastatin for Reduction of Myocardial Damage During
Angioplasty) Randomized Trial. J Am Coll Cardiol. 54:558–565.
2009.
|
11
|
Celik T, Kursaklioglu H, Iyisoy A, Kose S,
Kilic S, Amasyali B, Kardesoglu E and Isik E: The effects of prior
use of atorvastatin on coronary blood flow after primary
percutaneous coronary intervention in patients presenting with
acute myocardial infarction. Coron Artery Dis. 16:321–326. 2005.
View Article : Google Scholar
|
12
|
Ishii H, Ichimiya S, Kanashiro M, Aoyama
T, Ogawa Y, Murakami R, Amano T, Naruse K, Matsubara T and Murohara
T: Effects of receipt of chronic statin therapy before the onset of
acute myocardial infarction: a retrospective study in patients
undergoing primary percutaneous coronary intervention. Clin Ther.
28:1812–1819. 2006. View Article : Google Scholar
|
13
|
Iwakura K, Ito H, Kawano S, Okamura A,
Kurotobi T, Date M, Inoue K and Fujii K: Chronic pre-treatment of
statins is associated with the reduction of the no-reflow
phenomenon in the patients with reperfused acute myocardial
infarction. Eur Heart J. 27:534–539. 2006. View Article : Google Scholar : PubMed/NCBI
|
14
|
Lev EI, Kornowski R, Vaknin-Assa H,
Ben-Dor I, Brosh D, Teplitsky I, Fuchs S, Battler A and Assali A:
Effect of previous treatment with statins on outcome of patients
with ST-segment elevation myocardial infarction treated with
primary percutaneous coronary intervention. Am J Cardiol.
103:165–169. 2009. View Article : Google Scholar
|
15
|
Garot P, Bendaoud N, Lefevre T and Morice
MC: Favourable effect of statin therapy on early survival benefit
at the time of percutaneous coronary intervention for ST-elevation
myocardial infarction and shock. EuroIntervention. 6:350–355. 2010.
View Article : Google Scholar
|
16
|
Kim JS, Kim J, Choi D, et al: Efficacy of
high-dose atorvastatin loading before primary percutaneous coronary
intervention in ST-segment elevation myocardial infarction: the
STATIN STEMI trial. JACC Cardiovasc Interv. 3:332–339. 2010.
View Article : Google Scholar
|
17
|
Hahn JY, Kim HJ, Choi YJ, et al: Effects
of atorvastatin pretreatment on infarct size in patients with
ST-segment elevation myocardial infarction undergoing primary
percutaneous coronary intervention. Am Heart J. 162:1026–1033.
2011. View Article : Google Scholar
|
18
|
Li W, Fu X, Wang Y, et al: Beneficial
effects of high-dose atorvastatin pretreatment on renal function in
patients with acute ST-segment elevation myocardial infarction
undergoing emergency percutaneous coronary intervention.
Cardiology. 122:195–202. 2012. View Article : Google Scholar
|
19
|
Task Force on Myocardial Revascularization
of the European Society of Cardiology (ESC) and the European
Association for Cardio-Thoracic Surgery (EACTS); European
Association for Percutaneous Cardiovascular Interventions (EAPCI).
Wijns W, Kolh P, Danchin N, et al: Guidelines on myocardial
revascularization. Eur J Cardiothorac Surg. 38(Suppl): S1–S52.
2010. View Article : Google Scholar
|
20
|
Gensini GG: A more meaningful scoring
system for determining the severity of coronary heart disease. Am J
Cardiol. 51:6061983. View Article : Google Scholar : PubMed/NCBI
|
21
|
TIMI Study Group. The Thrombolysis in
Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med.
312:932–936. 1985. View Article : Google Scholar : PubMed/NCBI
|
22
|
van ‘t HAW, Liem A, de Boer MJ and
Zijlstra F: Clinical value of 12-lead electrocardiogram after
successful reperfusion therapy for acute myocardial infarction.
Zwolle Myocardial infarction Study Group. Lancet. 350:615–619.
1997.
|
23
|
Ignarro LJ, Buga GM, Wood KS, Byrns RE and
Chaudhuri G: Endothelium-derived relaxing factor produced and
released from artery and vein is nitric oxide. Proc Natl Acad Sci
USA. 84:9265–9269. 1987. View Article : Google Scholar : PubMed/NCBI
|
24
|
Radomski MW, Rees DD, Dutra A and Moncada
S: S-nitroso-glutathione inhibits platelet activation in vitro and
in vivo. Br J Pharmacol. 107:745–749. 1992. View Article : Google Scholar : PubMed/NCBI
|
25
|
Garg UC and Hassid A: Nitric
oxide-generating vasodilators and 8-bromo-cyclic guanosine
monophosphate inhibit mitogenesis and proliferation of cultured rat
vascular smooth muscle cells. J Clin Invest. 83:1774–1777. 1989.
View Article : Google Scholar
|
26
|
Kubes P, Suzuki M and Granger DN: Nitric
oxide: an endogenous modulator of leukocyte adhesion. Proc Natl
Acad Sci USA. 88:4651–4655. 1991. View Article : Google Scholar : PubMed/NCBI
|
27
|
Gauthier TW, Scalia R, Murohara T, Guo JP
and Lefer AM: Nitric oxide protects against leukocyte-endothelium
interactions in the early stages of hypercholesterolemia.
Arterioscler Thromb Vasc Biol. 15:1652–1659. 1995. View Article : Google Scholar : PubMed/NCBI
|
28
|
Anderson TJ, Meredith IT, Yeung AC, Frei
B, Selwyn AP and Ganz P: The effect of cholesterol-lowering and
antioxidant therapy on endothelium-dependent coronary vasomotion. N
Engl J Med. 332:488–493. 1995. View Article : Google Scholar : PubMed/NCBI
|
29
|
Treasure CB, Klein JL, Weintraub WS,
Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ,
Cedarholm JC and Alexander RW: Beneficial effects of
cholesterol-lowering therapy on the coronary endothelium in
patients with coronary artery disease. N Engl J Med. 332:481–487.
1995. View Article : Google Scholar : PubMed/NCBI
|
30
|
Lefer AM, Campbell B, Shin YK, Scalia R,
Hayward R and Lefer DJ: Simvastatin preserves the
ischemic-reperfused myocardium in normocholesterolemic rat hearts.
Circulation. 100:178–184. 1999. View Article : Google Scholar : PubMed/NCBI
|
31
|
Wassmann S, Faul A, Hennen B, Scheller B,
Bohm M and Nickenig G: Rapid effect of 3-hydroxy-3-methylglutaryl
coenzyme a reductase inhibition on coronary endothelial function.
Circ Res. 93:e98–e103. 2003. View Article : Google Scholar : PubMed/NCBI
|
32
|
Laufs U, La Fata V, Plutzky J and Liao JK:
Upregulation of endothelial nitric oxide synthase by HMG CoA
reductase inhibitors. Circulation. 97:1129–1135. 1998. View Article : Google Scholar : PubMed/NCBI
|
33
|
Danenberg HD, Szalai AJ, Swaminathan RV,
Peng L, Chen Z, Seifert P, Fay WP, Simon DI and Edelman ER:
Increased thrombosis after arterial injury in human C-reactive
protein-transgenic mice. Circulation. 108:512–515. 2003. View Article : Google Scholar : PubMed/NCBI
|
34
|
Bonz AW, Lengenfelder B, Jacobs M,
Strotmann J, Held S, Ertl G and Voelker W: Cytokine response after
percutaneous coronary intervention in stable angina: effect of
selective glycoprotein IIb/IIIa receptor antagonism. Am Heart J.
145:693–699. 2003. View Article : Google Scholar : PubMed/NCBI
|
35
|
Gomes WJ and Buffolo E: Coronary stenting
and inflammation: implications for further surgical and medical
treatment. Ann Thorac Surg. 81:1918–1925. 2006.PubMed/NCBI
|
36
|
Patti G, Chello M, Pasceri V, Colonna D,
Nusca A, Miglionico M, D’Ambrosio A, Covino E and Di SG: Protection
from procedural myocardial injury by atorvastatin is associated
with lower levels of adhesion molecules after percutaneous coronary
intervention: results from the ARMYDA-CAMs (Atorvastatin for
Reduction of MYocardial Damage during Angioplasty-Cell Adhesion
Molecules) substudy. J Am Coll Cardiol. 48:1560–1566. 2006.
|
37
|
Ostadal P, Alan D, Hajek P, Horak D,
Vejvoda J, Trefanec J, Mates M and Vojacek J: The effect of early
treatment by cerivastatin on the serum level of C-reactive protein,
interleukin-6, and interleukin-8 in the patients with unstable
angina and non-Q-wave myocardial infarction. Mol Cell Biochem.
246:45–50. 2003. View Article : Google Scholar : PubMed/NCBI
|